EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Advances in Radiotherapy for Glioblastoma and IDH-Mutant High-Grade Astrocytoma: A Biological and Mechanistic Perspective

Fatemeh Fekrmandi, Arnab Chakravarti

Cancers · 19.11.2026 · 18 (22) · 3698

DOI: 10.3390/cancers18223698 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 19.11.2026. Verfasst von Fatemeh Fekrmandi und 1 weiteren Autor:innen. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) and IDH-mutant high-grade astrocytoma remain therapeutically challenging. Historical GBM chemoradiation trials reported median overall survival of approximately 15–17 months; contemporary outcomes vary with molecular features, patient selection, and additional therapies. The 60 Gy in 30 fractions partial-brain regimen remains the reference standard for fit patients with newly diagnosed GBM. This narrative review examines radiotherapy based on its underlying biology, distinguishing GBM from IDH-mutant astrocytoma under the WHO molecular framework. It links DNA damage, cell-death programs, and radiation-induced immune signaling to the treatment response and DNA repair, stemness, hypoxia, and the microenvironment to resistance. These mechanisms motivate DNA-damage-response inhibitors, molecularly matched radiosensitizers, and immunotherapy combinations. Tumor treating fields are considered as an adjunctive non-ionizing modality. Proton therapy, FLASH, and MRI-guided adaptive radiotherapy are evaluated for their rationale and normal-tissue effects. Neurocognitive injury is discussed alongside the limitations of proposed hippocampal-sparing objectives. Personalization requires molecular selection and mechanism-matched treatment, with the clinical validation of benefits beyond dosimetry or imaging alone.

Zitieren

APA

Fekrmandi, F., & Chakravarti, A. (2026). Advances in Radiotherapy for Glioblastoma and IDH-Mutant High-Grade Astrocytoma: A Biological and Mechanistic Perspective. Cancers, 18(22), 3698. https://doi.org/10.3390/cancers18223698

Vancouver

Fekrmandi F, Chakravarti A. Advances in Radiotherapy for Glioblastoma and IDH-Mutant High-Grade Astrocytoma: A Biological and Mechanistic Perspective. Cancers. 2026;18(22):3698. doi:10.3390/cancers18223698

BibTeX
@article{Fekrmandi2026,
  author = {Fekrmandi, Fatemeh and Chakravarti, Arnab},
  title = {Advances in Radiotherapy for Glioblastoma and IDH-Mutant High-Grade Astrocytoma: A Biological and Mechanistic Perspective},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {22},
  pages = {3698},
  doi = {10.3390/cancers18223698}
}
Kostenlos starten →